Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 850 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... January 14, 2022 Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 Child Cancer Patient And His Dad Have A Little Fun When... October 3, 2019 Mom with Breast Cancer Who Had A Year to Live Goes... April 2, 2019 Load more HOT NEWS 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His... AI and remote monitoring are shaping a new patient journey in... Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously...
